RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--March 6, 2006--Icagen, Inc. (NASDAQ: ICGN) today announced that the Company has recently met the midway point of enrollment in the Company’s pivotal Phase III trial of ICA-17043, which is being conducted in collaboration with McNeil Consumer & Specialty Pharmaceuticals, for the chronic oral treatment of sickle cell disease, with 150 of the total expected study population of 300 patients now enrolled. The Company today also reaffirmed its prior guidance that it is targeting the second half of 2006 for the completion of enrollment.
